0HKD Stock Overview
Develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Axogen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.99 |
| 52 Week High | US$15.68 |
| 52 Week Low | US$5.57 |
| Beta | 1.13 |
| 11 Month Change | 1.29% |
| 3 Month Change | 3.84% |
| 1 Year Change | 119.71% |
| 33 Year Change | 10.23% |
| 5 Year Change | n/a |
| Change since IPO | -54.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0HKD | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 3.9% | -1.6% | 0.8% |
| 1Y | 119.7% | -4.4% | 6.6% |
Return vs Industry: 0HKD exceeded the UK Medical Equipment industry which returned -4.4% over the past year.
Return vs Market: 0HKD exceeded the UK Market which returned 6.6% over the past year.
Price Volatility
| 0HKD volatility | |
|---|---|
| 0HKD Average Weekly Movement | 9.0% |
| Medical Equipment Industry Average Movement | 6.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0HKD's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0HKD's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 427 | n/a | www.axogeninc.com |
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin.
Axogen, Inc. Fundamentals Summary
| 0HKD fundamental statistics | |
|---|---|
| Market cap | US$576.51m |
| Earnings (TTM) | -US$14.31m |
| Revenue (TTM) | US$180.86m |
3.2x
P/S Ratio-40.3x
P/E RatioIs 0HKD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0HKD income statement (TTM) | |
|---|---|
| Revenue | US$180.86m |
| Cost of Revenue | US$38.43m |
| Gross Profit | US$142.43m |
| Other Expenses | US$156.74m |
| Earnings | -US$14.31m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | 78.75% |
| Net Profit Margin | -7.91% |
| Debt/Equity Ratio | 50.0% |
How did 0HKD perform over the long term?
See historical performance and comparison